Health TrialsbyHealthPanel

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

ConditionsImmune ThrombocytopeniaThrombotic Thrombocytopenic PurpuraHemophilia A, AcquiredDisseminated Intravascular CoagulationThrombophiliaDeep Vein ThrombosisPulmonary EmbolismThrombotic MicroangiopathiesCoagulation Factor DeficiencyHemophilia AHemophilia BHemophilia B, AcquiredPlatelet DysfunctionArterial ThromboembolismBleeding DisorderThrombosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital

About this trial

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients who were diagnosed as thrombosis and hemostasis diseases.

Disqualifiers

Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.

Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.

According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.

Trial population

Patients who were diagnosed as thrombosis and hemostasis diseases, including immune thrombocytopenia, thrombotic thrombocytopenic purpura, hereditary and acquired Hemophilia, disseminated intravascular coagulation, pregnancy With ITP, pregnancy With prethrombotic state (such as protein C, protein S deficiency, etc.), deep vein thrombosis, pulmonary embolism, thrombocytopenia and coagulation abnormalities after hematopoietic stem cell transplantation, hereditary and acquired thrombophilia,hereditary hemorrhagic disease , et al.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Prognosis

To analyze the long-term prognosis of patients with thrombosis and hemostasis diseases, such as immune thrombocytopenia (ITP),thrombotic thrombocytopenic purpura, hereditary and acquired hemophilia, disseminated intravascular coagulation, pregnancy With ITP, pregnancy With prethrombotic state (such as protein C, protein S deficiency, etc.), deep vein thrombosis, pulmonary embolism, thrombotic microangiopathies, thrombocytopenia or coagulation abnormalities after hematopoietic stem cell transplantation, hereditary and acquired thrombophilia, platelet dysfunction,arterial thromboembolism, and hereditary hemorrhagic disease , et al., and analyze the risk factors associated with their prognosis.

Time frame
5 years

Secondary outcomes

1

Incidence

To describe the incidence of thrombosis and hemostasis diseases, and analyze the risk factors associated with these diseases.

Time frame
5 years
2

Distribution

The population characteristics of thrombosis and hemostasis diseases

Time frame
5 years
3

Overall response rate

To analyze the therapeutic efficacy of patients with thrombosis and hemostasis diseases, and analyze the impact factors associated with the efficacy.

Time frame
180 days
4

Long-term overall remission rate

Proportion of the participants with an overall remission.

Time frame
1 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University People's Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now